Anna Jewell

Anna Jewell is the director of services, research and innovation at Pancreatic Cancer UK, who remarked on the excitement surrounding the trial results of daraxonrasib, highlighting its potential to extend survival for advanced pancreatic cancer patients and the importance of making such treatments available.